Background/Aim: A recent survey has shown that insomnia is still a very common problem in maintenance hemodialysis (MHD) patients. The aim of the present study was to test the effects of zaleplon (ZAL), a new nonbenzodiazepine hypnotic drug, on the sleep quality of MHD patients with insomnia. Methods: The sleep quality was assessed by the Pittsburgh questionnaire in 10 patients (6 males/4 females) with insomnia on MHD; these patients underwent a randomized double-blind crossover study versus placebo (PLA). The main exclusion criterion was the presence of any possible cause of insomnia related to other concurrent diseases. Results: Treatment with ZAL significantly improved the total score of sleep quality (p < 0.03 vs. PLA). The analysis of the single components revealed that treatment with ZAL was associated with a higher subjective sleep quality (p < 0.01 vs. PLA) and a reduced sleep latency (p < 0.01 vs. PLA). The duration of sleep was not modified by ZAL, whereas a significant improvement was detected in habitual sleep efficacy (p < 0.05 vs. PLA). No peculiar side effect was recorded on ZAL. Blood parameters did not change, nor were differences recorded in the dialysis parameters (body weight gain, blood pressure) throughout the study. Conclusions: This study suggests that ZAL has a positive effect on the sleep quality in MHD patients. The absence of side effects and its pharmacodynamic properties make ZAL a useful drug in uremic patients.

Keywords:
Zaleplon, Hemodialysis, Sleep quality, Insomnia
1.
Sabbatini M, Minale B, Crispo A, Pisani A, Ragosta A, Esposito R, Cesaro A, Cianciaruso B, Andreucci VE: Insomnia in maintenance haemodialysis patients. Nephrol Dial Transplant 2002;17:852–856.
2.
Holley JL, Nespor S, Rault R: A comparison of reported sleep disorders in patients on chronic hemodialysis and continuous peritoneal dialysis. Am J Kidney Dis 1992;19:156–161.
3.
Walker S, Fine A, Kryger MH: Sleep complaints are common in a dialysis unit. Am J Kidney Dis 1995;26:751–756.
4.
Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Candela V, Labate C, Tassone F: Left ventricular hypertrophy and nocturnal hypoxemia in hemodialysis patients. J Hypertens 2001;19:287–293.
5.
Benz RL, Pressman MR, Hovick ET, Peterson DD: A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients. The SLEEPO Study. Am J Kidney Dis 1999;34:1089–1095.
6.
Doghramji PP: Treatment of insomnia with zaleplon, a novel sleep medication. Int J Clin Pract 2001;55:329–334.
7.
Weitzel KW, Wickman JM, Augustin SG, Strom JG: Zaleplon: A pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia. Clin Ther 2000;11:1254–1267.
8.
Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193–213.
9.
Ghosh AK, Sabbatini M: Sleep apnoea in ESRD patients: A review of evidence. Nephrol Dial Transplant 2002;17:1854.
10.
Strauss N, Simon R: Investigating a sequence of randomized phase II trials to discover promising treatments. Stat Med 1995;14:1479–1489.
11.
Kleinbaum DG: Applied Regression Analysis and Other Multivariate Methods. Belmont, Duxbury Press, 1997.
12.
Maczaj M: Pharmacological treatment of insomnia. Drugs 1993;45:44–55.
13.
Fry J, Scharf M, Mangano R, Fujimori M: Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group. Int Clin Psychopharmacol 2000;15:141–152.
14.
Elie R, Ruther R, Farr I, Emilien G, Salinas E: Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry 1999;60:536–544.
15.
Fillastre JP, Geoffroy-Josse S, Etienne I, Dhib M, Rosenzweig P, Danjou P, Dubruc C, Bianchetti G: Pharmacokinetics and pharmacodynamics of zolpidem following repeated doses in haemodialyzed uraemic patients. Fundam Clin Pharmacol 1993;7:1–9.
16.
Converse RL, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;327:1912–1918.
17.
Carpenter JS, Andrykowski MA: Psychometric evaluation of the Pittsburgh sleep quality index. J Psychosom Res 1998;45:5–13.
© 2003 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.